ASCO 2020：11项欧美研究入选口头报告，17项Poster报告

受全球最初冠疫情影响，原订于5翌年29日~6翌年2日在芝加哥举行的美国临床学就会（ASCO）年就会今年将首次以线上型式举办地，这是目前最大规模的线上盛就会。今天，代表大就会的简要出题公布，共103个sessions，中都国总计11项研究成果入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或罗德里格斯替尼加卡培他埠头应用于HER2+冠心病乳乳腺癌（PHOEBE）：一项III期随机次测试。

大舞台：冠心病乳乳腺癌

笔记：中都国医学科学院病房徐兵河系主任、马飞系主任，上海交通大学附设病房胡夕春系主任等

简要号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三特质性乳乳腺癌标准病人后卡培他埠头持续节拍肌肉注射的III期次测试（SYSUCC-001）。

大舞台：乳乳腺癌—发散/范围内/借助于病人

笔记：中都山大学保健中都心王之树森系主任等

简要号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

并用冠心病小脑的表型特质来预测小脑脊液中都反应器DNA检测的概率: 最初工具对抗据闻对手

大舞台：最初工具解决据闻问题

笔记：陈美芹 陈德兰等

简要号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为更早肝脏蛋白乳癌的中路病人：一项开放ID、随机、多中都心II/III期次测试。

大舞台：肠消化道乳癌—消化道十二指肠、坏死和实无

笔记：南京大学特罗斯季亚涅齐病房毕锋系主任、中都国人民解放军二七病房秦叔逵系主任等

简要号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中都国更早肝脏乳癌高血压阿帕替尼二线病人：一项随机、双盲对照、双盲III期研究成果

大舞台：肠消化道乳癌—消化道十二指肠、坏死和实无

笔记：中都国人民解放军二七病房秦叔逵系主任、南京大学特罗斯季亚涅齐病房陈秋系主任等

简要号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

更早复发性卵巢乳癌二次蛋白减灭术的一项随机III期次测试：SOC1 / SGOG-OV2。

回顾：医学乳乳腺癌

笔记：上海交通大学附设中都山病房臧荣余系主任等

简要：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈乳癌根治性子宫切除术后借助于病人中都的序贯放肌肉注射对比实际上放疗或同步放肌肉注射（STARS研究成果）：一项随机、对照、开放ID的III期次测试。

代表大就会：医学乳乳腺癌

笔记：中都山大学保健中都心黄鹤系主任、刘继红系主任等

简要号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：借助于吉非替尼对比肌肉注射应用于可切除的EGFR突变的N1-N2期NSCLC-随机III期临床次测试的最终总体共存研究。

回顾：肺乳癌—非小蛋白发散-范围内/小蛋白/其他胸部

笔记：东莞市人民病房吴一龙系主任等

简要号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突变寡移出非小蛋白肺乳癌高血压中路酪氨酸激酶抗病毒共同或不共同积极前线发散放疗：III期开放ID临床随机次测试（SINDAS）的中都期结果（NCT02893332）。

回顾：肺乳癌-非小蛋白移出

笔记：四川省人民病房曾铭系主任等

简要：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序性被害-1（PD-1）的人源化IgG4单克隆抗体共同阿昔替尼应用于冠心病水肿乳腺癌高血压的Ib期研究成果的总共存期和海洋生物圣万研究。

回顾：乳腺癌/皮肤乳癌

笔记：北京大学病房郭军、盛锡楠系主任等

简要：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的耐用性和结果：通用CAR-T蛋白首次人体次测试病人复发/难治性T蛋白急性淋巴蛋白乳癌（r/r T-ALL）的耐用性和。代表大就会：合作开发中都的病人技术-免疫病人。笔记：王之立马等简要：3013标语：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在更早十二指肠大块蛋白乳癌高血压中都的应用：一项随机的开放IDII期次测试（ORIENT-2）。代表大就会：肠消化道乳癌-消化道十二指肠乳癌、肝脏乳癌和实无道乳癌笔记：徐建明系主任等简要：4511标语：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T蛋白对髓母蛋白瘤的根除性病人代表大就会：中都枢神经系统笔记：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东简要：2522标语。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在更早错配修复弱点高血压中都的应用代表大就会：合作开发中都的病人学-免疫病人笔记：沈琳系主任等简要：3021标语。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART病人复发/难治性ACUTE淋巴蛋白乳癌/遗传病的首例人体临床次测试代表大就会: 合作开发性病人学-免疫病人笔记简介：张明志，陈东等简要：3026标语: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）共同应应用于更早实体瘤高血压的Ib期研究成果代表大就会：发展性病人学--底物靶向药物和海洋生态学笔记：龚继芳，沈琳系主任等简要：3523标语：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin共同紫杉醇和nedaplatin病人复发性或冠心病十二指肠大块蛋白乳癌（ESCC）高血压的II期研究成果。代表大就会：肠消化道乳癌-消化道十二指肠、坏死和实无道乳癌的研究成果笔记：王之志不强，陈玉红，王之德申，王之凤华，任超，谭琼 王之志不强、陈玉红、王之德深、王之凤华、任超、谭琼简要：4522标语：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.代表大就会：肠消化道乳癌-消化道十二指肠乳癌、肝脏乳癌和实无管乳癌的二线病人笔记：宋艳等简要：4524标语：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种血浆外体环状RNA分类器应用于初始恶性肿瘤时检测高等级乳癌的血浆外体环状RNA分类器：一项多中都心的回顾性研究成果代表大就会：脊柱生殖系统乳乳腺癌那是乳癌、睾丸乳癌和乳癌笔记简介：Liaoyuan Li等简要：5522标语。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 发散更早宫颈乳癌并发肌肉注射后的借助于肌肉注射代表大就会: 医学乳乳腺癌笔记简介： 陈珉珉等简要：6031标语：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼病人胰脏髓性乳癌的依赖性：基于ALTER01031次测试的研究。就会话：躯干笔记：长春市病房擅长于系主任简要：6526标语。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年纪对安洛替尼病人后高血压命运的影响: ALTER01031的亚组研究代表大就会：躯干笔记：长春市病房擅长于系主任简要：6527标语。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA研究预测I-IIIA期非小蛋白肺乳癌（NSCLC）高血压术后复发: GASTO1035和GASTO1018的结果代表大就会：肺乳癌-非小蛋白发散-范围内性/小蛋白/小蛋白/其他胸科乳乳腺癌笔记：Si-Yu Wang等简要：9023标语：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小蛋白肺乳癌（NSCLC）中都EGFR酪氨酸激酶抗病毒的最初型细菌性机制代表大就会:肺乳癌-非小蛋白冠心病肺乳癌笔记简介：赵昕，金恰巧，满宇，欧元人，和黄，薛武，杨少，范敏 赵昕、金恰巧、满宇、欧元人、和黄、薛武、杨绍、范敏简要：9528标语：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1次测试初叶乳腺癌总共存的替代起点代表大就会：乳腺癌/皮肤乳癌笔记：聂润聪，袁书不强，陈元芳，陈英波，周志伟 聂润聪、袁书不强、陈元芳、陈英波、周志伟简要：10030标语：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼病人复发或冠心病病症恶性骨高血压的II期研究成果代表大就会： 遗传性笔记：唐丽娜，牛晓辉，任弼时，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王之振、蔡启庆、涂崇奇、范正福、杨瑶简要：11525标语。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在更早遗传性高血压多线病人中都的耐用性和。代表大就会：遗传性笔记：姚伟涛，王之侯不强，张鹏，王之欣，杜最初辉，田志浩，牛晓颖 姚伟涛、王之侯不强、张鹏、王之鑫、杜鑫辉、田志超、牛晓英简要：11526标语：414